NEW YORK (GenomeWeb) – LGC announced today that it has acquired Berry and Associates in order to strengthen its nucleic acid chemistry portfolio.
Financial terms of the deal were not disclosed.
Dexter, Michigan-based Berry sells oligo reagents to customers in the pharmaceutical, clinical diagnostics, and academic research sectors. It also sells products to oligonucleotide synthesis companies and contract manufacturing organizations. The firm, which was founded in 1989, employs 14 people.
"Berry and Associates is a natural US counterpart to our UK-based LINK business, and it will become an important center for our North American Business," LGC Genomics President and Managing Director Brian Kim said in a statement. "Furthermore, Berry and Associates will increase supply chain resilience for our customers through multi-site manufacturing as well as local customer service and technical support in the US market."
Berry's owner, Lana Berry, also noted that the company's current portfolio of more than 400 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis, and hundreds of nucleosides, spacers, fluorescent markers, quenchers, and heterocycles "will sit nicely as part of LGC's expanding offering."
London-based LGC has been increasing its presence in the nucleic acid chemistry market in recent years through a massive series of acquisitions, including its buyouts of Biosearch Technologies in 2015, Prime Synthesis in 2016, Link Technologies in 2017, and BioAutomation earlier this year.
LGC also acquired Lucigen in February, expanding its commercial footprint in next-generation sequencing.